Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery

Martijn C de Wilde1, Cassia R Overk2, John W Sijben1

  • 1Nutricia Advanced Medical Nutrition, Nutricia Research, Utrecht, The Netherlands.

Abstract

Insights

Synaptic loss is an early Alzheimer's disease (AD) event, impacting presynaptic markers more than postsynaptic ones. This meta-analysis confirms widespread synaptic and molecular pathway disruption in AD pathogenesis.

Area of Science:

  • Neuroscience
  • Pathology
  • Biochemistry

Background:

  • Synaptic loss correlates with cognitive deficits in Alzheimer's disease (AD).
  • Oligomeric amyloid-β species are implicated in synaptic pathology.
  • Previous studies on AD synaptic pathology often had limited sample sizes.

Purpose of the Study:

  • To conduct a systematic meta-analysis of studies investigating synaptic and synaptic marker loss in Alzheimer's disease.
  • To establish the extent and timing of synaptic loss in AD pathogenesis.
  • To determine if presynaptic or postsynaptic markers are more affected in AD.

Main Methods:

  • A meta-analysis was performed on 417 publications reporting postmortem synapse and synaptic marker loss in AD patients.
  • Two separate meta-analyses were conducted using a unified database.
  • Standard mean differences were calculated to quantify the effects.

Main Results:

  • Meta-analysis confirmed that synaptic loss is an early event in AD pathogenesis across selected brain regions.
  • A second meta-analysis of 57 synaptic markers revealed a greater impact on presynaptic markers compared to postsynaptic markers.
  • Consistent synaptic loss was observed across brain regions.

Conclusions:

  • Synaptic loss is a consistent feature across brain regions in Alzheimer's disease.
  • Molecular machinery, including endosomal pathways, vesicular assembly, glutamate receptors, and axonal transport, is frequently affected in AD.
  • Presynaptic markers are more vulnerable than postsynaptic markers in AD synaptic pathology.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K